A12B4C3, an inhibitor of polynucleotide kinase/phosphatase enhances radio-sensitivity in PC-3 cells exposed to carbon ion beam
DOI:
https://doi.org/10.56511/JIPBS.2018.v5.i02.pp27-31Abstract
Cancer recurrence is a major problem of current radiotherapies like gamma radiation or High LET (Linear Energy Transfer) radiation. This problem can be overcome by the use of radio-modulator which will enhance cell killing and ⁄ or prevent cell regeneration after the treatment. Polynucleotide kinase / phosphatase (PNKP) plays an important role in DNA repair pathway. Accordingly, its inhibition can hamper the DNA damage repair processes and ultimately can suppress the recurrence of cancer. In this context, we have reported that following 24 hr 12Carbon ion beam combined with PNKPi (PNKP inhibitor) as radio-modulator enhanced the radio-sensitivity. Present study will elucidate the effect after 48 hr of 12Carbon ion beam in combination with PNKPi. We have checked the PC-3 cell viability through MTT assay, cell death mode by DAPI staining and cell cycle analysis through flow cytometry after 48 hr of irradiation (12Carbon ion beam having energy 62 MeV; equivalent to 5.16 MeV/nucleon with entrance LET 287 kev/μm) and in combination with PNKPi as radiomodulator. It was observed that PC-3 cell viability decreased following apoptosis when carbon ion beam was combined with PNKPi. Further, the cell cycle arrest was enhanced at S phase in combined treatment group compared to only irradiated cells. These findings suggest that, after 48 hr of carbon ion irradiation PNKP inhibition could enhance cellular radiosensitivity in prostate cancer cell line PC-3 by suppressing DNA damage repair pathway. The synergistic effect of PNKPi and carbon ion irradiation may be a promising method to avoid recurrence of cancerous cells following High LET carbon-ion radiation therapy.
Keywords:
High LET radiation, PNKP, PC-3, Gamma radiationDownloads
References
Haas GP, Delongchamps N, Brawley OW, Wang CY and Roza GDL: The worldwide epidemiology of prostate cancer: perspective from autopsy studies. Cancer Journal of Urology 2008; 15:3866-3871.
Siegel R, Miller K and Jemal A: Cancer statistics. CA Cancer J Clin 2018; 68:7-30.
Shukla P, Mathur V, Kumar A, Khedgikar V, Teja BV, Chaudhary D, KushwahaP, Bora HK, Konwar R, Trivedi R and Mishra PR: Nanoemulsion Based Concomitant Delivery of Curcumin and Etoposide: Impact on Cross Talk Between Prostate Cancer Cells and Osteoblast During Metastasis. Journal of Biomedical Nanotechnology 2014; 10: 3381 – 3391.
Jain S, Saxena S and Kumar A: Epidemiology of prostate cancer in India. Meta gene 2014; 2: 596 – 605.
Coquelle N, Shahriari ZH, Bernstein N, Green R and Glover JNM: Structural basis for the phosphatase activity of polynucleotide kinase/phosphatase on single and double-stranded DNA substrates. PNAS 2011; 108:21022 – 21027.
Davidson D, Amrein L, Panasci L and Aloyz R: Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond. Frontiers in pharmacology 2013; 4:1-7.
Curtin NJ and Szabo C : Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 2013; 34:1217-56.
Fukumura A, Tsujii H, Kamada T et al: Carbon-ion radiotherapy: clinical aspects and related dosimetry. Radiat. Prot. Dosimetry 2009; 137:149 – 55.
Kramer M, Scholz M: Rapid calculation of biological effects in ion radiotherapy. Phys Med Biol 2006; 5:1959-1970.
Schellenberg MJ and Williams RS: DNA end processing by polynucleotide kinase/phosphatase. PNAS 2011; 108:20855 – 20856.
Mereniuk TR, EI Gendy MA, Mendes-Pereira AM, Ana MMP, Lord C J, Ghosh S, Foley E, Ashworth A and Weinfeld M: Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase. Mol Cancer Ther 2013; 12:2135 – 2144.
Allinson SL : DNA end-processing enzyme polynucleotide kinase as a potential target in the treatment of Cancer. Future Oncol ogy 2010; 6:1031-42.
Freschauf GK, Mani RS, Mereniuk TR, Fanta M, Virgen CA, Dianov GL et al: Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase. J. Biol. Chem 2010; 285: 2351 – 2360.
Freschauf GK, Karimi-Busheri F, Ulaczyk-Lesanko A, Mereniuk TR, Ahrens A, Koshy JM, Rasouli-Nia A, Pasarj P, Holmes CFB, Rininsland FR, Hall DG and Weinfeld M: Identification of a small molecule inhibitor of the human DNA repair enzyme polynucleotide Kinase/Phosphatase. Cancer Res 2009; 69: 7739-7746.
Zereshkian A, Leyton JV, Cai Z, Bergstrom D, Weinfeld M and Reilly RM: The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 111In-NLS-7G3 radioimmuno conjugates. Nucl Med Biol 2014; 41: 377 – 383.
Lee Y, Sunada S, Hirakawa H, Fujimori A, Nickoloff JA and Okayasu R: TAS-116, a novel hsp90 inhibitor, selectively enhances radiosensitivity of human cancer cells to x-rays and carbon ion radiation. Mol Cancer Ther. 2017; 16: 16-24.
Kelley MR, Logsdon D and Fishel ML: Targeting DNA repair pathways for cancer treatment: what's new?. Future Oncology 2015; 10:1215-1237.
Srivastava P, Sarma A and Chaturvedi CM: Targeting DNA repair with PNKP inhibition sensitizes radioresistant prostate cancer cells to high LET radiation. Plos One 2018; 13:1-14.
Ghorai A, Sarma A, Chowdhury P and Ghosh U: PARP-1 depletion in combination with carbon ion exposure significantly reduces MMPs activity and overall increases TIMPs expression in cultured HeLa cells. Radiation Oncology 2016; 11: 1-13.
Kothari A, Barua P, Archunan M, Rani K, Subramanian ET, Pujari G et al: ASPIRE: An automated sample positioning and irradiation system for radiation biology experiments at Inter University Accelerator Centre, New Delhi. Radiation Measurements 2015; 76:17-22.
Jiegler JF, Bierserk JP and Littmark U: Stopping and ranges of ions in matter. Pergamon Press, New York.
Kraft-Weyrather W, Kraft G, Ritter S, Scholz M and Stanton JA: The preparation of biological targets for heavy-ion experiments up to 20MeV/u: Nuclear Instruments and Methods in Physics Research A 1989; 282:2227.
Plumb JA, Milroy R and Kaye S B: Effects of the pH dependence of 3- (4,5-dimethylthiazol-2-yl)-2,5diphenyl-tetrazolium bromide – formazan absorption on chemosensitivity determined by a novel tetrazoliumbased assay. Cancer Research 1989; 49: 4435 – 4440.
Mori E, Takahashi A, Yamakawa N, Kirita T and Ohnishi T: High LET heavy ion radiation induces p53 independent apoptosis. J Radiat Res 2009; 50:37 – 42.
Published
How to Cite
Issue
Section
Copyright (c) 2018 Pallavi Srivastava, Asitikantha Sarma, Chandra Mohini Chaturvedi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at